earnings
confidence high
sentiment positive
materiality 0.80
Stereotaxis Q2 revenue surges 95% to $8.8M; net loss narrows to $3.8M
Stereotaxis, Inc.
2025-Q2 EPS
reported -$0.12
vs consensus -$0.07
▼ miss
(-81.0%)
- Revenue $8.8M (+95% YoY, +18% seq); system revenue $3.0M (vs $0.2M), recurring $5.8M (+35% YoY).
- Net loss $3.8M vs $5.8M; adjusted net loss $1.3M vs $3.3M; gross margin 52%.
- Cash $7.0M at June 30; July $12.5M financing closed; pro forma cash $18.8M, no debt.
- Guidance: double-digit FY2025 revenue growth; Q4 recurring ~$7M; system $2-3M/quarter.
- FDA clearance for MAGiC Sweep catheter; initial sales in Q2; further approvals expected near-term.